Digitalis Ventures
VC Fund
New York, United States
Digitalis Ventures is a VC fund in New York focused on Biotechnology and Health Care. Digitalis is a venture capital firm that that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, inventors, and scientists across all stages of venture investing, and our investments span the full continuum of the healthcare ecosystem. It was founded in 2016 and is Headquartered in New York,New York with regional offices in Boston, Los Angeles, and San Francisco.
- Total investments:
- 114
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Digitalis Ventures invests in
Stages Digitalis Ventures invests in
Countries Digitalis Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.5M–$15M
- Series A
- $8.6M–$66M
- Series B
- $13M–$132M
Investment Focus
Industry
- Biotechnology 29 (25%)
- Health Care 22 (19%)
- Medical 14 (12%)
- Therapeutics 14 (12%)
- Pet 8 (7%)
Stage
- Series A 32 (28%)
- Series B 22 (19%)
- Seed 21 (18%)
- Series C 5 (4%)
- Funding Round 3 (3%)
Country
- United States 52 (46%)
- United Kingdom 5 (4%)
- China 2 (2%)
- Canada 1 (1%)
- Australia 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amit Bansal
Partner
|
Partner | Total investments: 3 | Find email | |
Cindy Cole
Partner
|
Partner | Total investments: 13 | Find email | |
Dac Nguye
Technical Partner
|
Technical Partner | Total investments: 0 | Find email | |
Drew Taylor
Partner
|
Partner | Total investments: 5 | Find email | |
Geoffrey W. Smith
founder and managing partner
|
founder and managing partner | Total investments: 20 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Omni
|
Omni is a plant-based pet food company from the UK, that is developing healthy, sustainable food for dogs. | $14.6M / Series A / Jun 22, 2026 | |
Neion Bio
|
Neion Bio uses advances in stem cell biology and genetic engineering to completely reimagine the biopharmaceutical production process. | $23M / Series A / Jun 11, 2026 | |
Rejuvenate Bio
|
Rejuvenate Bio is a biotechnology company that develops novel gene therapies for dogs. The company's therapy provides a solution for the mitral valve disease to stop the progression of heart failure in dogs, thus providing pets with extended overall health and maximal lifespan. It was founded in 2017 and is based in San Diego, CA. | $6M / Venture - Series Unknown / Jun 08, 2026 | |
Travv
|
Travv is a startup focused on veterinary diagnostics powered by AI. It offers cloud-based services connecting veterinarians worldwide with expert diagnosticians for streamlined workflows in areas like radiology, pathology, and cardiology. | $1.6M / Seed / May 06, 2026 | |
Clasp.com
|
Stride Funding (AlmaPact Inc.) is a mission-driven company focused on enabling debt-free lives for students, by supplementing student loans with flexible income sharing agreements. Unlike student loans that lock students into a single rigid payment, Stride’s payments rise and fall with a student’s income so that payments are always affordable. Thecompany has been recognized as a visionary leader by FinTech analysts for its efforts on income protection and career support. Stride was created by students, for students, aiming to change student lives for the better. The company has been recognized by Harvard and MIT as a top new venture. Stride has received venture investments from GSV Accelerate, Slow Ventures, Sinai Ventures and Pear VC; and its strategic investors include Strada Education. Its advisors include serial entrepreneurs, Doug Levin and Tina Sharkey. Fund your Future, Find your Stride! | $20M / Series B / Mar 26, 2026 | |
Varda
|
Varda is a space manufacturing startup that focuses on creating products in space for terrestrial applications. They aim to manufacture things in space that benefit from low gravity. The company intends to create an infrastructure that harvests source materials for new products in-space via asteroid mining.The company was founded in 2020 byDelian Asparouhov and Trae Stephens. | Series D / Feb 17, 2026 | |
EpiBiologics
|
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | |
Protego Biopharma
|
Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M / Series B / Dec 01, 2025 | |
T-Therapeutics
|
T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. . | $32M / Series A / Nov 13, 2025 | |
Faeth Therapeutics
|
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy.The company was founded totranslate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians. | $25M / Series A / Oct 20, 2025 | |
| See all 114 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Digitalis Ventures invest in?
Digitalis Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 114 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Digitalis Ventures's check size?
Digitalis Ventures typically joins rounds of $1.5M–$15M at Seed, $8.6M–$66M at Series A and $13M–$132M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Digitalis Ventures participates in.
How do I contact Digitalis Ventures?
Public channels for Digitalis Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Digitalis Ventures?
The team at Digitalis Ventures includes Amit Bansal (Partner), Cindy Cole (Partner) and Dac Nguye (Technical Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
